NEW ORLEANS, Oct. 04, 2022 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Louisiana Attorney General Charles C. Foti, Jr., remind investors that they have until November 28, 2022 Lead plaintiff’s motions in a securities class action against Centessa Pharmaceuticals plc CNTAif they purchased or otherwise acquired the Company’s securities and/or purchased the Company’s American Depositary Shares (“ADSs”) between May 28, 2021 and June 1, 2022 inclusive (the “Collection Period”), as disclosed by the Company or otherwise acquired May 2021 Initial Public Offering (the “IPO”). This lawsuit is pending in the United States District Court for the Central District of California.
What you can do
If you have purchased Centessa securities or ADSs as described above and would like to discuss your legal rights and how this case may affect you and your right to compensation for your economic loss, you may contact KSF Managing Partner at no obligation or cost to you Lewis contact Kahn toll-free at 1-877-515-1850 or email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more. If you wish to be a lead plaintiff in this class action lawsuit, you must file a petition with the court November 28, 2022.
About the lawsuit
Centessa and certain of its officers are alleged to have failed to disclose material information during the Class Period and/or in the registration statement and prospectus issued in connection with the IPO, in violation of federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, the following: (i) lixivaptan, the Company’s drug product, was less safe than the Company had made it out to be; (ii) the company has overstated the clinical efficacy and commercial viability of lixivaptan; (iii) ZF874, another of the company’s medicines, was less safe than the company had represented; (iv) the Company has overstated the clinical efficacy and commercial efficacy of ZF874…
